N
118.92
9.17 (8.36%)
| 前收盘价格 | 109.75 |
| 收盘价格 | 123.00 |
| 成交量 | 5,008,976 |
| 平均成交量 (3个月) | 1,586,858 |
| 市值 | 11,765,730,304 |
| 市盈率 (P/E TTM) | 33.31 |
| 预期市盈率 (P/E Forward) | 21.46 |
| 价格/销量 (P/S) | 5.21 |
| 股市价格/股市净资产 (P/B) | 4.74 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 - 4 Aug 2025 |
| 营业毛利率 | 14.49% |
| 营业利益率 (TTM) | 20.87% |
| 稀释每股收益 (EPS TTM) | 3.29 |
| 季度收入增长率 (YOY) | 21.80% |
| 季度盈利增长率 (YOY) | -30.20% |
| 总债务/股东权益 (D/E MRQ) | 19.14% |
| 流动比率 (MRQ) | 3.40 |
| 营业现金流 (OCF TTM) | 595.40 M |
| 杠杆自由现金流 (LFCF TTM) | 457.98 M |
| 资产报酬率 (ROA TTM) | 10.45% |
| 股东权益报酬率 (ROE TTM) | 14.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
| 股票 | Neurocrine Biosciences, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.6
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.63 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.08% |
| 机构持股比例 | 99.17% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 185.00 (Evercore ISI Group, 55.57%) | 购买 |
| 中 | 154.00 (29.50%) | |
| 低 | 115.00 (BMO Capital, -3.30%) | 保留 |
| 平均值 | 156.09 (31.26%) | |
| 总计 | 10 购买, 1 保留 | |
| 平均价格@调整类型 | 109.34 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BMO Capital | 06 May 2025 | 115.00 (-3.30%) | 保留 | 109.68 |
| Canaccord Genuity | 06 May 2025 | 160.00 (34.54%) | 购买 | 109.68 |
| 28 Apr 2025 | 158.00 (32.86%) | 购买 | 106.46 | |
| Guggenheim | 06 May 2025 | 165.00 (38.75%) | 购买 | 109.68 |
| 10 Feb 2025 | 163.00 (37.07%) | 购买 | 118.81 | |
| Needham | 06 May 2025 | 139.00 (16.89%) | 购买 | 109.68 |
| 15 Apr 2025 | 138.00 (16.04%) | 购买 | 96.16 | |
| Piper Sandler | 06 May 2025 | 154.00 (29.50%) | 购买 | 109.68 |
| RBC Capital | 06 May 2025 | 145.00 (21.93%) | 购买 | 109.68 |
| 14 Apr 2025 | 137.00 (15.20%) | 购买 | 94.89 | |
| UBS | 06 May 2025 | 152.00 (27.82%) | 购买 | 109.68 |
| 04 Apr 2025 | 137.00 (15.20%) | 购买 | 95.65 | |
| Evercore ISI Group | 24 Apr 2025 | 185.00 (55.57%) | 购买 | 105.76 |
| HC Wainwright & Co. | 22 Apr 2025 | 168.00 (41.27%) | 购买 | 101.74 |
| 24 Feb 2025 | 185.00 (55.57%) | 购买 | 119.11 | |
| JP Morgan | 26 Mar 2025 | 184.00 (54.73%) | 购买 | 114.45 |
| Morgan Stanley | 07 Mar 2025 | 150.00 (26.14%) | 购买 | 113.04 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合